S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Wall Street inches higher toward edge of bull market
NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Angion Biomedica MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
-0.12mentions of Angion Biomedica in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.51) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

649th out of 981 stocks

Pharmaceutical Preparations Industry

313th out of 464 stocks


ANGN stock logo

About Angion Biomedica (NASDAQ:ANGN) Stock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

8-K: Angion Biomedica Corp.
WARNING: Do You Invest with these Banks
Take a close look at the investment banks above. Because if you have stocks with any of these brokerages... These new political developments WILL affect you.
Angion Biomedica (ANGN) Set to Announce Earnings on Tuesday
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
Angion Biomedica Corp. (ANGN)
See More Headlines


ANGN Company Calendar

Last Earnings
11/12/2021
Today
6/06/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Net Income
$-38,810,000.00
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Book Value
$1.32 per share

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60

Key Executives

  • Dr. Jay R. Venkatesan M.B.A. (Age 50)
    M.D., Ph.D., Pres, CEO & Chairman
    Comp: $587.1k
  • Mr. Gregory S. Curhan (Age 60)
    Chief Financial Officer
  • Ms. Jennifer J. Rhodes J.D.Ms. Jennifer J. Rhodes J.D. (Age 52)
    Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.
  • Mr. Daniel Iazzetti
    VP of HR
  • Bruce Rich
    Assistant Sec.













ANGN Stock - Frequently Asked Questions

Should I buy or sell Angion Biomedica stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ANGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANGN, but not buy additional shares or sell existing shares.
View ANGN analyst ratings
or view top-rated stocks.

When is Angion Biomedica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ANGN earnings forecast
.

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $1.08 million.

When did Angion Biomedica's stock split?

Shares of Angion Biomedica reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

(ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What is Angion Biomedica's stock symbol?

Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN."

Who are Angion Biomedica's major shareholders?

Angion Biomedica's stock is owned by many different retail and institutional investors. Top institutional investors include CM Management LLC (2.66%) and Renaissance Technologies LLC (0.31%). Insiders that own company stock include Allen Nissenson, Itzhak Goldberg, Jay Venkatesan, Jennifer J Rhodes, Jennifer J Rhodes, John F Neylan and Victor F Ganzi.
View institutional ownership trends
.

How do I buy shares of Angion Biomedica?

Shares of ANGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Angion Biomedica make?

Angion Biomedica (NASDAQ:ANGN) has a market capitalization of $0.00 and generates $2.30 million in revenue each year.

How can I contact Angion Biomedica?

Angion Biomedica's mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The official website for the company is www.angion.com. The company can be reached via phone at 415-655-4899 or via email at daniel@lifesciadvisors.com.

This page (NASDAQ:ANGN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -